ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in early stage Gallbladder Cancer
P. Iyer, S. V. Shrikhande, M. Ranjan, A. Joshi, R. Prasad, N. Gardi, R. Thorat, S. Salunkhe, B. Dharavath, B. Sahoo, P. Chandrani, H. Kore, B. Mohanty, V. Chaudhari, A. Choughule, , A. Dutt
This study identifies ERBB2 and KRAS mutations in early-stage gallbladder cancer and shows their impact on response to EGFR inhibitors.
bioRxiv · Mar 28, 2018Cancer Biology